Exenatide is a GLP-1 receptor agonist.

Exenatide is a GLP-1 receptor agonist.

• A. It inhibits DPP-4
• B. It is a SGLT2 inhibitor
• C. It is a GLP-1 receptor agonist
• D. False

Answer: (C)

Exenatide acts as a GLP-1 receptor agonist, meaning it binds to GLP-1 receptors and activates the same signaling pathways as the natural incretin GLP-1. This enhances glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon when glucose is high, slows gastric emptying, and promotes satiety, all of which help lower blood glucose and can aid in weight loss in type 2 diabetes. It is not a DPP-4 inhibitor; DPP-4 inhibitors work by blocking the enzyme that degrades endogenous GLP-1, thereby increasing its levels rather than directly activating the receptor. It is not an SGLT2 inhibitor, which reduces blood glucose by blocking glucose reabsorption in the kidneys. Therefore, the statement that Exenatide is a GLP-1 receptor agonist is correct.

Exenatide acts as a GLP-1 receptor agonist, meaning it binds to GLP-1 receptors and activates the same signaling pathways as the natural incretin GLP-1. This enhances glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon when glucose is high, slows gastric emptying, and promotes satiety, all of which help lower blood glucose and can aid in weight loss in type 2 diabetes. It is not a DPP-4 inhibitor; DPP-4 inhibitors work by blocking the enzyme that degrades endogenous GLP-1, thereby increasing its levels rather than directly activating the receptor. It is not an SGLT2 inhibitor, which reduces blood glucose by blocking glucose reabsorption in the kidneys. Therefore, the statement that Exenatide is a GLP-1 receptor agonist is correct.